• HER connection
  • Her connection

    Discover a program designed to support patients with knowledge and information about HER2+ breast cancer.

    Three ways to connect:

  • Receive Updates
    Personalized information to support your treatment

  • Support Line
    Call 866.449.HER2 Nurses available 24/7

  • Online Live Chat
    Nurses available 8am EST to 8pm EST.

Insurance Information

We're here to help

Handling insurance matters can be difficult on your own. That's where Herceptin Access Solutions™ can help. Although you are not required to use this free information resource, you may find it reassuring to know that Herceptin Access Solutions is here for you if you need help with your insurance matters.

What is Herceptin Access Solutions?

Herceptin Access Solutions

Herceptin Access Solutions, sponsored by Genentech, Inc., is a free resource that can provide patients and their healthcare providers with helpful insurance reimbursement information regarding Herceptin®

Herceptin Access Solutions reimbursement specialists can offer you assistance with:

  • Investigating your Herceptin insurance coverage benefits
  • Assessing whether prior authorization, from your insurance, is needed for your Herceptin therapy
  • Appealing denied Herceptin claims
  • Providing patient assistance resources

You can access more information about Herceptin Access Solutions on the internet at www.HerceptinAccessSolutions.com, or speak to a Herceptin Access Solutions reimbursement specialist at:

Toll-free: 1-888-249-4918 (6 AM to 5 PM Pacific time Monday-Friday)

What if I don't have insurance?

Not all Herceptin (trastuzumab) patients have complete medical coverage, so we've provided some alternative resources.

Please note: This page contains the Web address to a number of other organizations that may offer useful information. We suggest visiting those sites directly to obtain information on specific details of coverage, and educational and financial support services for Herceptin. Unless otherwise indicated, Genentech, Inc. is not a partner or affiliated with any company listed. The availability of insurance coverage and financial assistance varies from company to company, plan to plan, and state to state. Genentech, Inc. does not imply or guarantee that your insurance company nor any other company will provide coverage or assistance for Herceptin. Genentech, Inc. is not responsible for any decisions of partial or noncoverage of Herceptin.

Genentech® Access to Care Foundation

Although Genentech's products are covered by most government and private insurance, Genentech has established the Genentech Access to Care Foundation for its marketed products.We are committed to eligible patients having access to all of our drugs for approved indications. For eligible patients who are treated in the United States, Genentech will provide product to those who cannot afford to pay because we believe it is the right thing to do.

Who is Herceptin for?

Herceptin is approved for the adjuvant treatment of HER2-overexpressing, node-positive or node-negative (ER/PR-negative or with one high-risk feature)† breast cancer. Herceptin can be used several different ways:

  • As part of a treatment regimen including doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel
  • With docetaxel and carboplatin
  • As a single agent following multi-modality anthracycline-based therapy

Herceptin in combination with paclitaxel is approved for the first-line treatment of HER2-overexpressing metastatic breast cancer. Herceptin as a single agent is approved for treatment of HER2-overexpressing breast cancer in patients who have received one or more chemotherapy regimens for metastatic disease.

† High-risk is defined as ER/PR positive with one of the following features: tumor size >2 cm, age <35 years, or tumor grade 2 or 3.

What important safety information should I know about Herceptin?

Herceptin treatment can result in heart problems, including those without symptoms (reduced heart function) and those with symptoms (congestive heart failure). The risk and seriousness of these heart problems were highest in people who received both Herceptin and a certain type of chemotherapy (anthracycline). Your doctor will stop or strongly consider stopping Herceptin if you have a significant drop in your heart function.

You should be monitored for decreased heart function before your first dose of Herceptin, and frequently during the time you are receiving Herceptin and after your last dose of Herceptin. If you must permanently or temporarily stop Herceptin due to heart problems, you should be monitored more frequently. In one study with Herceptin and certain types of chemotherapy, an inadequate blood supply to the heart occurred.

Some patients have had serious infusion reactions and lung problems; fatal infusion reactions have been reported. In most cases, these reactions occurred during or within 24 hours of receiving Herceptin. Your Herceptin infusion should be temporarily stopped if you have shortness of breath or very low blood pressure. Your doctor will monitor you until these symptoms go away. If you have a severe allergic reaction, swelling, lung problems, inflammation of the lung, or severe shortness of breath, your doctor may need to completely stop your Herceptin treatment.

Worsening of low white blood cell counts associated with chemotherapy has also occurred.

Herceptin can cause low amniotic fluid levels and harm to the fetus when taken by a pregnant woman.

The most common side effects associated with Herceptin were fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, shortness of breath, rash, low white and red blood cells, and muscle pain.

Because everyone is different, it is not possible to predict what side effects any one person will have. If you have questions or concerns about side effects, talk to your doctor.

Please see the Herceptin full Prescribing Information including Boxed WARNINGS and additional important safety information.



Herceptin® (trastuzumab)Herceptin® (trastuzumab)

Adjuvant Care Is defined as additional treatment given after the main treatment plan to decrease the chance of recurrence. Adjuvant therapy for breast cancer can include chemotherapy, hormone therapy, radiation therapy, or biological therapy

Metastatic Breast Cancer Breast cancer that has spread to other sites in the body; also referred to as invasive or infiltrating

close

Share this page

Email this page